Last reviewed 2026-04-23 · How we verify

SP5M001 inj

SP5M001 inj is a small molecule drug that targets the SGLT2 receptor.

SP5M001 inj is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular events reduction.

At a glance

Mechanism of action

By inhibiting SGLT2, SP5M001 inj reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. SP5M001 inj has shown promise in improving glycemic control and reducing cardiovascular events in clinical trials.

Approved indications

• Type 2 diabetes
• Cardiovascular events reduction

Common side effects

• Nausea
• Diarrhea
• Vomiting
• Hypotension
• Increased urination

Key clinical trials

• Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.